Thermo Fisher sets $4 billion stock buyback plan

WALTHAM, Mass. - Thermo Fisher Scientific Inc. (NYSE:), a leading company in the scientific services industry, announced today that its Board of Directors has approved a new share repurchase program. The company, known for providing a range of scientific solutions, is set to buy back $4 billion of its common stock. This new repurchase plan is to take place on the open market or through negotiated transactions, and notably, it does not have an expiration date.

The fresh repurchase initiative comes as a replacement for Thermo Fisher's previous buyback plan, which still had $1 billion remaining. The action reflects a common corporate strategy of returning value to shareholders and potentially boosting the company's earnings per share by reducing the number of shares outstanding.

Thermo Fisher, with a reported annual revenue of around $40 billion, positions itself as a global leader in serving the science community. The company's mission is to support customers across various sectors, including life sciences research, laboratory productivity, diagnostics, and the development of therapies. Thermo Fisher's portfolio includes a collection of well-known brands such as Thermo Scientific, Applied Biosystems, Invitrogen, and Fisher Scientific, amongst others.

The announcement of the share repurchase plan is based on a press release statement from Thermo Fisher Scientific Inc. Share buybacks are often used by companies to signal confidence in their financial health and future prospects. This move by Thermo Fisher could be interpreted as a positive sign by investors, as the company appears to be taking steps to actively manage its capital allocation.

While the company has not specified the timing of the repurchases, the absence of an expiration date provides Thermo Fisher with flexibility in managing the buyback process. This strategic decision by the Board of Directors could have implications for the company's stock performance, depending on market conditions and investor reactions.

Investors and market watchers will likely keep an eye on Thermo Fisher's stock (NYSE:TMO) as the company proceeds with its repurchase plan. The company's approach to share buybacks may also reflect broader trends in corporate finance and investor relations within the scientific services industry.

In other recent news, Thermo Fisher Scientific has been making significant financial and strategic strides. The company reported a robust financial performance in its third-quarter earnings call, announcing a revenue of $10.6 billion and an adjusted earnings per share (EPS) of $5.28. Thermo Fisher also raised its full-year adjusted EPS guidance to a range of $21.35 to $22.07, while maintaining its revenue forecast within the range of $42.4 billion to $43.3 billion.

In addition to these financial achievements, Thermo Fisher's Board of Directors authorized a quarterly cash dividend of $0.39 per common share, demonstrating the company's commitment to delivering value to shareholders. The firm's financial position allows for consistent dividend payments, along with other shareholder-focused activities.

Baird revised its price target for Thermo Fisher shares to $622 from the previous $632, maintaining an Outperform rating, indicating confidence in the company's ability to navigate current market conditions. Furthermore, Thermo Fisher's strategic growth was highlighted by a partnership with the National Cancer Institute. These recent developments reflect Thermo Fisher's ongoing efforts to meet its long-term goals amid market uncertainties.

InvestingPro Insights

Thermo Fisher Scientific's new $4 billion share repurchase program aligns with the company's history of shareholder-friendly actions. According to InvestingPro data, Thermo Fisher has maintained dividend payments for 13 consecutive years and has raised its dividend for 7 consecutive years. This consistent track record of returning value to shareholders is further emphasized by an InvestingPro Tip indicating that management has been aggressively buying back shares.

The company's financial health appears robust, with a market capitalization of $203.88 billion and revenues of $42.37 billion over the last twelve months as of Q3 2024. Despite a slight revenue decline of 2.42% over the same period, Thermo Fisher maintains a strong gross profit margin of 40.68% and an operating income margin of 17.42%.

An interesting InvestingPro Tip suggests that the stock's Relative Strength Index (RSI) indicates it may be in oversold territory. This could potentially present an opportunity for investors, especially considering the company's new buyback program. However, it's worth noting that Thermo Fisher is trading at a relatively high P/E ratio of 33.39, which may reflect investor optimism about its future prospects.

For those interested in a deeper analysis, InvestingPro offers 13 additional tips for Thermo Fisher Scientific, providing a more comprehensive view of the company's financial position and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.